These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1803860)

  • 41. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
    Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
    Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells.
    Dawson MI; Chao WR; Pine P; Jong L; Hobbs PD; Rudd CK; Quick TC; Niles RM; Zhang XK; Lombardo A
    Cancer Res; 1995 Oct; 55(19):4446-51. PubMed ID: 7671258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.
    Kopreski MS; Lipton A; Harvey HA; Kumar R
    Anticancer Res; 1996; 16(1):433-6. PubMed ID: 8615649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones.
    Schmidt RE; Hercend T; Fox DA; Bensussan A; Bartley G; Daley JF; Schlossman SF; Reinherz EL; Ritz J
    J Immunol; 1985 Jul; 135(1):672-8. PubMed ID: 3923116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro.
    Paciotti GF; Tamarkin L
    Mol Endocrinol; 1988 May; 2(5):459-64. PubMed ID: 2971135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells.
    Obiri NI; Siegel JP; Varricchio F; Puri RK
    Clin Exp Immunol; 1994 Jan; 95(1):148-55. PubMed ID: 8287600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.
    Novick D; Shulman LM; Chen L; Revel M
    Cytokine; 1992 Jan; 4(1):6-11. PubMed ID: 1617157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-6 enhances motility of breast carcinoma cells.
    Sehgal PB; Tamm I
    EXS; 1991; 59():178-93. PubMed ID: 1655518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells.
    Tamm I; Cardinale I; Krueger J; Murphy JS; May LT; Sehgal PB
    J Exp Med; 1989 Nov; 170(5):1649-69. PubMed ID: 2553849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased adherence of interleukin 6-treated breast carcinoma cells can lead to separation from neighbors after mitosis.
    Tamm I; Cardinale I; Murphy JS
    Proc Natl Acad Sci U S A; 1991 May; 88(10):4414-8. PubMed ID: 1852008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells.
    Sehgal PB
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of Potential Key Genes and Pathways for Inflammatory Breast Cancer Based on GEO and TCGA Databases.
    Lv Q; Liu Y; Huang H; Zhu M; Wu J; Meng D
    Onco Targets Ther; 2020; 13():5541-5550. PubMed ID: 32606769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6.
    Dittmer A; Lange T; Leyh B; Dittmer J
    Int J Oncol; 2020 Jan; 56(1):258-272. PubMed ID: 31789400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer.
    Morrow RJ; Etemadi N; Yeo B; Ernst M
    Mediators Inflamm; 2017; 2017():4754827. PubMed ID: 28607534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells.
    Sehgal PB
    Oncogene; 2010 Apr; 29(17):2599-600; author reply 2601-3. PubMed ID: 20140019
    [No Abstract]   [Full Text] [Related]  

  • 56. The functions of cytokines and their uses in toxicology.
    Foster JR
    Int J Exp Pathol; 2001 Jun; 82(3):171-92. PubMed ID: 11488991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells.
    Tamm I; Cardinale I; Kikuchi T; Krueger JG
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4338-42. PubMed ID: 8183909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction by interleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA.
    Harroch S; Revel M; Chebath J
    EMBO J; 1994 Apr; 13(8):1942-9. PubMed ID: 8168491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cell-adhesion-disrupting action of interleukin 6 in human ductal breast carcinoma cells.
    Tamm I; Kikuchi T; Cardinale I; Krueger JG
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3329-33. PubMed ID: 7512730
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.